Video: Knock on Wood| Webinar: ACR/CHEST ILD Guidelines in Practice
fa-facebookfa-linkedinfa-youtube-playfa-rss

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

  • Conditions
    • Axial Spondyloarthritis
    • Gout and Crystalline Arthritis
    • Myositis
    • Osteoarthritis and Bone Disorders
    • Pain Syndromes
    • Pediatric Conditions
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
    • Systemic Sclerosis
    • Vasculitis
    • Other Rheumatic Conditions
  • FocusRheum
    • ANCA-Associated Vasculitis
    • Axial Spondyloarthritis
    • Gout
    • Lupus Nephritis
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Systemic Lupus Erythematosus
  • Guidance
    • Clinical Criteria/Guidelines
    • Ethics
    • Legal Updates
    • Legislation & Advocacy
    • Meeting Reports
      • ACR Convergence
      • Other ACR meetings
      • EULAR/Other
    • Research Rheum
  • Drug Updates
    • Analgesics
    • Biologics/DMARDs
  • Practice Support
    • Billing/Coding
    • EMRs
    • Facility
    • Insurance
    • QA/QI
    • Technology
    • Workforce
  • Opinion
    • Patient Perspective
    • Profiles
    • Rheuminations
      • Video
    • Speak Out Rheum
  • Career
    • ACR ExamRheum
    • Awards
    • Career Development
  • ACR
    • ACR Home
    • ACR Convergence
    • ACR Guidelines
    • Journals
      • ACR Open Rheumatology
      • Arthritis & Rheumatology
      • Arthritis Care & Research
    • From the College
    • Events/CME
    • President’s Perspective
  • Search

Search results for: hip OA

The Tortured Path to the Cortisone Discovery

Thomas R. Collins  |  February 17, 2019

CHICAGO—The path to the discovery of cortisone—a top-selling, important drug, with dozens of indications—was complicated by failure, false moves, desperation and obsession. The tale, recounted in the Philip Hench, MD, Memorial Lecture: Crossroads of History & Hope: Discovery & First Use of Cortisone for RA at the 2018 ACR/ARHP Annual Meeting in October, is an…

Filed under:Meeting ReportsRheumatoid Arthritis Tagged with:2018 ACR/ARHP Annual MeetingcortisoneResearch Funding

From Kolkata to Chicago: The ACR-IRA International Exchange Program

Debanjali Sinha, MD  |  February 17, 2019

The ACR–Indian Rheumatology Association (IRA) International Fellows Exchange Program was developed in 2016 to foster scientific collaboration between members of the ACR and junior rheumatologists representing the IRA. I was lucky enough to be selected to participate in this exchange initiative, and I can’t thank these two organizations enough for working together to provide this…

Filed under:Education & TrainingProfessional Topics Tagged with:2018 ACR/ARHP Annual MeetingDr. Debanjali SinhaIndian Rheumatology Association (IRA)

WindNight / shutterstock.com

Why & How Our Biologic Drug Discussion with Patients Should Evolve

Paul H. Caldron, DO, PhD, MBA, & John R.P. Tesser, MD  |  February 17, 2019

As we turn the corner on the second decade of biologic use for rheumatic disorders, a reappraisal of approach in our communication with patients is due. In practice, the impact these agents have on patients’ lives justifies the friction rheumatologists face when connecting patients to them. You can understand why older rheumatologists who apprenticed on…

Filed under:Biologics/DMARDsResearch RheumRheumatoid ArthritisSpeak Out Rheum Tagged with:OpinionSpeak Out Rheumatology

Cancer-Associated Myositis: A Case Report & Review of the Literature

Cancer-Associated Myositis: A Case Report & Review of the Literature

Osman Bhatty, MD, Rouhin Sen, MD, & Joseph Nahas, MD  |  February 17, 2019

Since it was first reported in 1916, a correlation between inflammatory myopathies and cancer has been noted in several studies. Population studies have confirmed this relationship, and the phrase cancer-associated myopathy has entered the vernacular. Over the past decade, research efforts have shifted toward revealing associations between autoantibodies and clinical phenotypes. One subset of auto-antigens…

Filed under:ConditionsMyositisOther Rheumatic Conditions Tagged with:Cancercarcinoid syndromecase reportdermatomyositis

Large-Vessel Involvement Is an Independent Risk Factor Predicting GCA Mortality

Carina Stanton  |  February 14, 2019

At diagnosis, temporal artery biopsy results and large-vessel involvement of patients with giant cell arteritis may be stronger predictors of mortality than cardiovascular risk factors…

Filed under:ConditionsVasculitis Tagged with:GCAgiant cell arteritis (GCA)mortality

Moments That the Words Don’t Reach

Philip Seo, MD, MHS  |  February 12, 2019

There are moments that the words don’t reach There is suffering too terrible to name You hold your child as tight as you can And push away the unimaginable                                     —Lin Manuel Miranda A friend of mine was killed a few days ago. By the time you read this column, the scars will have already started…

Filed under:OpinionProfessional TopicsRheuminationsSpeak Out Rheum Tagged with:bereavementgriefsudden bereavementsudden death

Alterations in Macrophage Activation May Signal a Lupus Flare

Lara C. Pullen, PhD  |  February 11, 2019

New data suggest myeloid cells in SLE patients skew B and T cell activation status toward the M1 proinflammatory phenotype, thereby directing SLE flares and remission…

Filed under:ConditionsSystemic Lupus Erythematosus Tagged with:genemyeloid cellsSLEsystemic lupus erythematosus (SLE)

Lead Effectively: Leaders Are Made, not Born

Paula Marchetta, MD, MBA  |  February 8, 2019

Every year at the end of January, ACR and ARP volunteers gather in Atlanta to learn more about a subject we seldom are taught in any formal way in our professional training: leadership. The 2019 Leadership Development Conference took place on Saturday, Jan. 26 and offered participants a unique opportunity to step away from their…

Filed under:American College of RheumatologyCareer DevelopmentPresident's PerspectiveProfessional Topics Tagged with:2019 Leadership Development ConferenceLeadershipMichael A. Roberto

Not-for-Profit to Offer 20 Generic Drugs in 2019 to Alleviate Shortages

Jilian Mincer  |  January 25, 2019

(Reuters)—A new not-for-profit supplier of generic drugs formed by a consortium of hospitals systems said it expects this year to be able to provide about 20 products to alleviate shortages of medicines used during surgeries and to treat life-threatening conditions, such as septic shock. Since the start-up of Civica Rx spearheaded by Intermountain Healthcare was…

Filed under:Drug Updates Tagged with:Drug shortagegeneric drugsIntermountain Healthcare

Med Student Documentation Guidelines Need Careful Implementation

Will Boggs, MD  |  January 18, 2019

NEW YORK (Reuters Health)—New student-documentation guidelines from the Centers for Medicare and Medicaid Services (CMS) require careful implementation to avoid reductions in meaningful teaching physician involvement, according to a new report. The revised Medicare Claims Processing Manual allows the teaching physician to verify in the medical record any student documentation of services, rather than re-documenting…

Filed under:Career DevelopmentEducation & TrainingProfessional Topics Tagged with:Centers for Medicare & Medicaid Services (CMS)Medicare Claims Processing Manuastudent-documentation guidelines

  • « Previous Page
  • 1
  • …
  • 151
  • 152
  • 153
  • 154
  • 155
  • …
  • 329
  • Next Page »
  • About Us
  • Meet the Editors
  • Issue Archives
  • Contribute
  • Advertise
  • Contact Us
fa-facebookfa-linkedinfa-youtube-playfa-rss
  • Copyright © 2025 by John Wiley & Sons, Inc. All rights reserved, including rights for text and data mining and training of artificial technologies or similar technologies. ISSN 1931-3268 (print). ISSN 1931-3209 (online).
  • DEI Statement
  • Privacy Policy
  • Terms of Use
  • Cookie Preferences